- Trial Demonstrated a Median Progression-Free Survival of 14.9 Months Using Encorafenib and Binimetinib Combination -
PR Newswire
BOULDER, Colo., March 22, 2018
PR Newswire
BOULDER, Colo., March 22, 2018
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey